Predominance of Rotavirus G8P[8] in a City in Chile, a Country Without Rotavirus Vaccination - 06/10/18
Doi : 10.1016/j.jpeds.2018.08.037
Yalda Lucero, MD, PhD 1, Miguel O'Ryan, MD 1, 2, * 
, Giulia Liparoti 3, Nicole Huerta 1, Nora Mamani 1, Sasirekha Ramani, PhD 4, Anne J. Lagomarcino, MSc 1, Felipe Del Canto, PhD 1, Jorge Quense, PhD 5
, Giulia Liparoti 3, Nicole Huerta 1, Nora Mamani 1, Sasirekha Ramani, PhD 4, Anne J. Lagomarcino, MSc 1, Felipe Del Canto, PhD 1, Jorge Quense, PhD 5 1 Microbiology and Mycology Program, ICBM, Faculty of Medicine, University of Chile, Santiago, Chile
2 Millenium Institute of Immunology and Immunotherapy, University of Chile, Santiago, Chile
3 Department of Medicine, University of Perugia, Perugia, Italy
4 Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX
5 Geography Institute, Pontificia Universidad Católica de Chile, Santiago, Chile
*Reprint requests: Miguel O'Ryan, MD, Microbiology and Mycology Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Ave Independencia 1027, Santiago, Chile.Microbiology and Mycology ProgramInstitute of Biomedical SciencesFaculty of MedicineUniversity of ChileAve Independencia 1027SantiagoChile
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Saturday 06 October 2018
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
Rotavirus G8P[8] infection has been common in Africa, but rare in the Americas. Among 23 rotavirus episodes observed during 18 months of surveillance of 100 families in Chile, 11 (48%) were identified as G8P[8]. Genotypes from these strains shared >99% identity with rotavirus sequences described in Asia, and may be misclassified as mixed G8/G12.
Le texte complet de cet article est disponible en PDF.Keywords : rotavirus, genotypes, G8, G8P[8], VP7, America, Latin America
Abbreviations : ADE, RT-PCR
Plan
| Supported by Takeda Vaccines Inc through an Investigator-Initiated Sponsored Research Grant. The funding agency had no role in study design; collection, management, analysis, or interpretation of the data; and preparation, review, or approval of the manuscript. M.O. receives financial support from an Investigator-Initiated Sponsored Research Grant. The other authors declare no conflict of interest. |
|
| Portions of this study were presented at the European Society for Pediatric Infectious Diseases, May 28-June 2, 2018, Malmo, Sweden. |
© 2018
Elsevier Inc. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?